Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.
Schepisi G., Farolfi A., Conteduca V., Martignano F., De Lisi D., Ravaglia G., et al. (2017). Immunotherapy for prostate cancer: Where we are headed. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 18(12), 1-12 [10.3390/ijms18122627].
Immunotherapy for prostate cancer: Where we are headed
Farolfi A.;Ravaglia G.;Menna C.;Barone D.;De Giorgi U.
2017
Abstract
Prostate cancer is one of the most common malignant neoplasms in men worldwide, and is the fifth cause of cancer-related death. In recent years, a new generation of therapies have been approved for the management of metastatic disease. Moreover, the development of new immunotherapeutic drugs has become a novel frontier for the treatment of several tumor types; to date, numerous studies have investigated their potential activity, including in prostate cancer. In this article, we discuss the role of emerging immunotherapeutic drugs in prostate cancer patients.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
